UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer
- UCB’s expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum’s discovery of treatments for solid tumors
- Ariceum’s expertise in radiopharmaceuticals and labelling technology will aid UCB’s discovery of treatments for immune-related diseases
- Potential to expand Ariceum’s pipeline with three new programs at discovery stage
Berlin, Germany, and Brussels, Belgium, 11 May 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers,and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced an exclusive, strategic research collaboration agreement to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.